Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul:34 Suppl 1:S4-11.
doi: 10.1007/s10875-014-0019-2. Epub 2014 Apr 1.

Natural autoantibodies to Fcγ receptors in intravenous immunoglobulins

Affiliations

Natural autoantibodies to Fcγ receptors in intravenous immunoglobulins

Hicham Bouhlal et al. J Clin Immunol. 2014 Jul.

Abstract

A considerable progress has been achieved in the comprehension of the cellular and molecular mechanisms that account for the therapeutic benefit of intravenous immunoglobulin (IVIg) in several autoimmune and inflammatory conditions. However, the precise mechanisms responsible for such a wide range of biological activities have not been proven unambiguously. A wide range of specificities have been identified within IVIg including idiotypes of immunoglobulins, T cell receptor, HLA molecules, several cell surface molecules of immunological importance such as CD4, CD5, Fas, BAFF, cytokines and cytokine receptors, chemokine receptors, CD40 among others. Here we identify and characterize the natural autoantibodies of IgG isotype directed against the human Fc receptors. We show that the F(ab')2 of IVIg recognize the FcγRIII (CD16) and FcγRII (CD32). Interestingly, the immunopurified anti-FcγIII and anti-FcγII antibodies isolated from IVIg bind soluble and membrane-bound FcR and inhibit rosette formation. Altogether, these results along with previous reports provide pointers on the existence of functionally relevant natural autoantibodies towards a wide range of self-motifs that may participate in regulation of the immune response. Their presence in the therapeutic immunoglobulin preparations may explain at least in part, the beneficial effect of IVIg in autoimmune diseases.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Biol Chem. 2007 Nov 30;282(48):34817-27 - PubMed
    1. J Autoimmun. 2013 Mar;41:46-9 - PubMed
    1. Blood. 1993 May 1;81(9):2413-9 - PubMed
    1. Curr Opin Immunol. 1995 Dec;7(6):812-8 - PubMed
    1. J Chromatogr B Biomed Appl. 1994 Dec 9;662(2):197-207 - PubMed

MeSH terms